Surufatinib ( Generic (approved in China; limited global availability) )

Targeted Therapy

med_ema_not_submitted

med_spain_not_available 2 Clinical Trials

Description

Surufatinib is approved in China for the treatment of advanced neuroendocrine tumors and has shown efficacy in certain gastrointestinal stromal tumors. In colorectal cancer, it remains investigational with ongoing clinical trials evaluating its potential role as a targeted therapy, particularly in combination with other agents or in refractory cases.

Mechanism of Action

Surufatinib is a small molecule receptor tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptors (VEGFR) and colony-stimulating factor-1 receptor (CSF-1R), thereby inhibiting tumor angiogenesis and macrophage-mediated tumor progression.

Side Effects

Hypertension; proteinuria; gastrointestinal adverse events (nausea Vomiting); fatigue; thromboembolic events

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT05472948 med_phase_prefix2

Archived

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

China

NCT04579757 med_phase_prefix1

Terminated

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

United States

Quick Info

Brand Name	Generic (approved in China; limited global availability)
Category	Targeted Therapy
Estado EMA	med_ema_not_submitted
Acceso España	med_spain_not_available
Clinical Trials	2

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.

Surufatinib (** Generic (approved in China; limited global availability) **)